

Teus van Laar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42368/publications.pdf>

Version: 2024-02-01

104
papers

5,063
citations

126901

33
h-index

95259

68
g-index

110
all docs

110
docs citations

110
times ranked

5107
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	27.0	1,111
2	Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 37-44.	10.2	607
3	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	27.0	225
4	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 749-759.	10.2	203
5	Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. <i>Brain</i> , 2009, 132, 2980-2993.	7.6	163
6	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	2.2	126
7	Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands. <i>Environment International</i> , 2017, 107, 100-110.	10.0	121
8	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	3.9	111
9	Peripheral neuropathy in Parkinson's disease: Levodopa exposure and implications for duodenal delivery. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 501-507.	2.2	99
10	Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 40-49.	2.2	91
11	Postoperative gait deterioration after bilateral subthalamic nucleus stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 2404-2406.	3.9	87
12	Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle. <i>Movement Disorders</i> , 2017, 32, 1253-1254.	3.9	73
13	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> , 2017, 32, 1482-1486.	3.9	67
14	Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson's Disease. <i>Clinical Pharmacokinetics</i> , 1999, 37, 257-271.	3.5	66
15	Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. <i>Movement Disorders</i> , 2008, 23, 1906-1912.	3.9	66
16	Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2016, 23, 17-22.	2.2	63
17	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2014, 37, 9-16.	0.7	62
18	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	3.9	61

#	ARTICLE	IF	CITATIONS
19	Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 437-450.	6.4	54
20	Intrathecal delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. <i>Pharmaceutical Research</i> , 1997, 14, 1804-1810.	3.5	52
21	A Case-Control Study of the Protective Effect of Alcohol, Coffee, and Cigarette Consumption on Parkinson Disease Risk: Time-Since-Cessation Modifies the Effect of Tobacco Smoking. <i>PLoS ONE</i> , 2014, 9, e95297.	2.5	52
22	Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. <i>Movement Disorders</i> , 2007, 22, 2430-2435.	3.9	50
23	Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 270-274.	2.2	48
24	Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. <i>Movement Disorders</i> , 2011, 26, 142-147.	3.9	48
25	Effective Delivery of Apomorphine in the Management of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 89-103.	0.7	48
26	Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study. <i>Journal of Psychosomatic Research</i> , 2015, 79, 190-194.	2.6	46
27	Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 71-72.	2.2	42
28	A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. <i>Movement Disorders</i> , 2020, 35, 1667-1674.	3.9	41
29	Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 642-650.	3.9	41
30	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 35-40.	2.2	40
31	A Guideline for Parkinson's Disease Nurse Specialists, with Recommendations for Clinical Practice. <i>Journal of Parkinson's Disease</i> , 2017, 7, 749-754.	2.8	39
32	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	2.2	39
33	Deep Brain Stimulation for Essential Tremor: A Comparison of Targets. <i>World Neurosurgery</i> , 2018, 110, e580-e584.	1.3	38
34	Levodopa-Induced Response Fluctuations in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2003, 17, 475-489.	5.9	36
35	Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 33, 90-95.	2.2	36
36	Clinical Relevance of Pharmacological and Physiological Data in Intrathecal Baclofen Therapy. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 2199-2206.	0.9	34

#	ARTICLE	IF	CITATIONS
37	Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 33-38.	2.2	34
38	Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. <i>Movement Disorders</i> , 2008, 23, 1532-1540.	3.9	33
39	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S49-S55.	2.2	31
40	SCOPA-cognition cutoff value for detection of Parkinson's disease dementia. <i>Movement Disorders</i> , 2011, 26, 1881-1886.	3.9	30
41	Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands. <i>Occupational and Environmental Medicine</i> , 2014, 71, 757-764.	2.8	29
42	Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 331-334.	3.9	27
43	Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. <i>Movement Disorders</i> , 2022, 37, 713-723.	3.9	27
44	Mental slowness in patients with Parkinson's disease: Associations with cognitive functions?. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 844-852.	1.3	26
45	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 246-253.	3.9	25
46	Improved Gait Performance in a Patient With Hereditary Spastic Paraplegia After a Continuous Intrathecal Baclofen Test Infusion and Subsequent Pump Implantation: A Case Report. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, 1166-1169.	0.9	23
47	Characteristics of dystonia in the 18p deletion syndrome, including a new case. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 880-882.	1.4	22
48	Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2017, 21, 283-289.	6.3	21
49	Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. <i>Movement Disorders</i> , 1998, 13, 176-178.	3.9	20
50	Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 635-639.	2.2	20
51	Objective Versus Subjective Measures of Executive Functions: Predictors of Participation and Quality of Life in Parkinson Disease?. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 2181-2187.	0.9	20
52	[¹⁸ F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer. <i>Movement Disorders</i> , 2019, 34, 924-926.	3.9	20
53	The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study. <i>Movement Disorders</i> , 1998, 13, 52-55.	3.9	19
54	The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations. <i>Clinical Neuropharmacology</i> , 2009, 32, 266-268.	0.7	19

#	ARTICLE	IF	CITATIONS
55	The treatment of early Parkinson's disease: levodopa rehabilitated. <i>Practical Neurology</i> , 2011, 11, 145-152.	1.1	19
56	Unmet needs in Parkinson's disease: New horizons in a changing landscape. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S2-S8.	2.2	19
57	Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation—A Prospective Noninferiority Study. <i>Neuromodulation</i> , 2019, 22, 472-477.	0.8	18
58	Multicenter Validation of Metabolic Abnormalities Related to <sc>PSP</sc> According to the <sc>MDSâ€PSP</sc> Criteria. <i>Movement Disorders</i> , 2020, 35, 2009-2018.	3.9	18
59	The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 13-27.	2.7	17
60	Study protocol of the DUTch PARKinson Cohort (DUPARC): a prospective, observational study of de novo Parkinsonâ€™s disease patients for the identification and validation of biomarkers for Parkinsonâ€™s disease subtypes, progression and pathophysiology. <i>BMC Neurology</i> , 2020, 20, 245.	1.8	17
61	Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data. <i>Scientific Reports</i> , 2021, 11, 11751.	3.3	17
62	Lasting visual hallucinations in visual deprivation; fMRI correlates and the influence of rTMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1295-1296.	1.9	16
63	Quick Titration of Pergolide in Cotreatment with Domperidone Is Safe and Effective. <i>Clinical Neuropharmacology</i> , 2001, 24, 177-180.	0.7	15
64	Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FE0BV PET study. <i>Aging Brain</i> , 2022, 2, 100039.	1.3	15
65	Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EARly Parkinsonâ€™s disease: the LEAP-study. <i>BMC Neurology</i> , 2015, 15, 236.	1.8	14
66	Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases. <i>Contact Dermatitis</i> , 2018, 79, 316-318.	1.4	13
67	Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinsonâ€™s disease. <i>International Archives of Occupational and Environmental Health</i> , 2015, 88, 227-234.	2.3	12
68	Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 71-84.	2.8	12
69	Pre-Movement Cortico-Muscular Dynamics Underlying Improved Parkinson Gait Initiation after Instructed Arm Swing. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1675-1693.	2.8	12
70	Oscillatory activity and cortical coherence of the nucleus basalis of Meynert in Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 102-106.	2.2	11
71	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2018, 41, 14-19.	0.7	11
72	Effectiveness of ReSET; a strategic executive treatment for executive dysfunctioning in patients with Parkinsonâ€™s disease. <i>Neuropsychological Rehabilitation</i> , 2020, 30, 67-84.	1.6	11

#	ARTICLE	IF	CITATIONS
73	How Many Patients would Benefit from Steering Technology for Deep Brain Stimulation?. <i>Brain Stimulation</i> , 2016, 9, 144-145.	1.6	10
74	Optimal Parameters of Deep Brain Stimulation in Essential Tremor: A Meta-Analysis and Novel Programming Strategy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1855.	2.4	10
75	The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S22-S27.	2.2	9
76	The Intraoperative Microlesion Effect Positively Correlates With the Short-Term Clinical Effect of Deep Brain Stimulation in Parkinson's Disease. <i>Neuromodulation</i> , 2023, 26, 459-465.	0.8	9
77	Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 96-101.	2.2	9
78	Population Pharmacokinetics of Apomorphine in Patients with Parkinson's Disease. <i>Drug Investigation</i> , 1994, 7, 183-190.	0.6	8
79	Fallacious falls. <i>Journal of Neurology</i> , 2005, 252, 1271-1273.	3.6	8
80	Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 935-944.	2.8	8
81	Long-Term Patient-Reported Outcome of Radiofrequency Thalamotomy for Tremor. <i>Stereotactic and Functional Neurosurgery</i> , 2020, 98, 187-192.	1.5	8
82	Self-Reported Visual Complaints in People with Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2022, 12, 785-806.	2.8	8
83	Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 345-371.	1.4	8
84	Intraoperative Quantification of MDS-UPDRS Tremor Measurements Using 3D Accelerometry: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2275.	2.4	8
85	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 523-537.	2.8	7
86	The added value of semimicroelectrode recording in deep brain stimulation of the subthalamic nucleus for Parkinson disease. <i>Neurosurgical Focus</i> , 2013, 35, E3.	2.3	6
87	rTMS treatment of visual hallucinations using a connectivity-based targeting method - A case study. <i>Brain Stimulation</i> , 2019, 12, 1622-1624.	1.6	6
88	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinson's disease: A Prospective Analysis of the Thai Apomorphine Registry. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 146-151.	2.2	6
89	Systematic analysis of PINK1 variants of unknown significance shows intact mitophagy function for most variants. <i>Npj Parkinson's Disease</i> , 2021, 7, 113.	5.3	6
90	Postural and gait symptoms in de novo Parkinson's disease patients correlate with cholinergic white matter pathology. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 43-49.	2.2	6

#	ARTICLE	IF	CITATIONS
91	Lateral and Medial Ventral Occipitotemporal Regions Interact During the Recognition of Images Revealed from Noise. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 678.	2.0	5
92	Successful treatment of intractable visual hallucinations with 5-HT2A antagonist ketanserin. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224340.	0.5	4
93	Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. <i>International Journal of Bio-medical Computing</i> , 1994, 36, 143-150.	0.5	3
94	Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications". <i>Parkinsonism and Related Disorders</i> , 2022, 97, 99-100.	2.2	3
95	Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature. <i>Neuromodulation</i> , 2018, 21, 527-531.	0.8	2
96	Introduction: The Gut-Brain Axis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S279-S279.	2.8	2
97	Treatment of subcutaneous nodules after infusion of apomorphine; a biopsy-controlled study comparing 4 frequently used therapies. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 38-40.	2.2	1
98	Serendipitous Stimulation of Nucleus Basalis of Meynert "The Effect of Unintentional, Long-Term High-Frequency Stimulation on Cognition in Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 337.	2.4	1
99	1.IS.3. On-going developments in the use of apomorphine in complex Parkinson's disease (Britannia) Tj ETQq1 1 0.784314 rgBT /Over	2.2	0
100	Continuous Drug Delivery with Levodopa/Carbidopa Infusion: Review and First Data of a Dutch Cohort. <i>CNS Spectrums</i> , 2008, 13, 11-14.	1.2	0
101	Deep Brain Stimulation in a Dopaminergic Non-responsive Patient With Parkinson's Disease: Case Report and Systematic Review. <i>Brain Stimulation</i> , 2015, 8, 983-985.	1.6	0
102	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e27-e28.	2.2	0
103	Effect of pharmacist-led interventions on motor symptoms in Parkinson's patients: A pilot study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e87-e88.	2.2	0
104	Diepe hersenstimulatie bij de ziekte van Parkinson. , 2016, , 77-83.		0